ApocalypseSurvival
472 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by ApocalypseSurvival from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Johnson & Johnson Commits $200 million to Speed Ebola Vaccine Development and Expand Production | Johnson & Johnson

Johnson & Johnson Commits $200 million to Speed Ebola Vaccine Development and Expand Production | Johnson & Johnson | ApocalypseSurvival | Scoop.it

 

 Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments, and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen.

 

The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), combines a Janssen preventative vaccine with a vaccine from Bavarian Nordic, a biotechnology company based in Denmark. This combination vaccine regimen has shown promising results in preclinical studies, and is now planned to be tested for safety and immunogenicity in healthy volunteers in Europe, the United States of America and Africa starting in early January. Janssen is targeting production of more than one million doses of the vaccine regimen in 2015, 250,000 of which are expected to be released for broad application in clinical trials by May 2015.

The regimen consists of two vaccine components that are based on AdVac® technology from Crucell Holland B.V., which is part of the Janssen Pharmaceutical Companies, and the MVA-BN® technology from Bavarian Nordic. The research collaboration for a monovalent vaccine targeting the Zaire strain of the Ebola virus is part of an ongoing development program for a multivalent vaccine against other virus strains that cause disease in humans, including Ebola and Marburg viruses. 

As part of an overall commitment to advance innovations that address unmet medical needs worldwide, a team of dedicated experts has been assigned to focus on bringing this preventative vaccine to people in need. The commitment by Johnson & Johnson includes an equity investment in Bavarian Nordic to provide capital for the development, testing and production of Bavarian Nordic’s vaccine. Janssen will take the lead in funding and developing both components of the combination vaccine regimen.

.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 22, 2014 10:48 AM

J&J intends to produce 1 million doses of the new NIAID+Bavarian Nordic Ebola vaccine at Janssen R&D lab/plant.

Rescooped by ApocalypseSurvival from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

U.S. Emergency Labs Ready To Work On Ebola Drugs If Asked

U.S. Emergency Labs Ready To Work On Ebola Drugs If Asked | ApocalypseSurvival | Scoop.it
(Repeating story first sent on Aug 9 to additional subscribers) By Sharon Begley and Toni Clarke NEW YORK/WASHINGTON, Aug 9 (Reuters) - All three U.S. facilities established to quickly make vaccines and therapeutics in...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 12, 2014 2:21 PM

The US emergency labs and production facilities are ready to scale up producing Ebola drugs, mabs and vaccines if funded.

 

The facilities are mainly for US use but can supply drugs to Allies and WHO.

Rescooped by ApocalypseSurvival from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Did ZMapp cure two Americans with Ebola? Experts can't say, yet

Did ZMapp cure two Americans with Ebola? Experts can't say, yet | ApocalypseSurvival | Scoop.it
Though Dr. Kent Brantly and Nancy Writebol have been discharged from Emory University Hospital after their terrifying bouts with Ebola, it's unclear if the experimental drug they were given is what led to their cure.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 22, 2014 11:16 AM

Not sure as 50% of Ebola patients recover with good care and follow up. ZMAPP was given in small amounts. Out of 3 patients given ZMAPP, 2 survived and 1 Spanish patient died.